Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers
Faizan-e- Mustaffa, Muhammad Shahbaz Aslam, Muhammad Junaid · 2026
Read Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers by Faizan-e- Mustaffa, Muhammad Shahbaz Aslam, Muhammad Junaid (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13624245.txt.
Description
Faizan-e-Mustaffa, Muhammad Shahbaz Aslam, and Muhammad Junaid review the next generation of CAR-T cell therapy, where a patient's immune cells are engineered to hunt cancer. The first versions transformed blood cancer care, yet they struggle with tumours that shed their markers, cells that wear out, side effects, and prices and methods that limit reach.
The review sorts engineering ideas by how proven they are, weighing clinical, regulatory, and laboratory evidence from 2022 to 2026. Covered designs include armoured cells carrying payloads, dual-target and logic-gated systems that demand two signals before attacking. Also covered: universal off-the-shelf cells, gene editing by CRISPR and base and prime editors, and methods building the cells inside the body using fat-particle delivery. Combinations with checkpoint drugs, radiation, and cancer-killing viruses aim at solid tumours. The authors close with manufacturing, safety, and durability hurdles that gate wider use.
Catalog record
| CREATOR | Faizan-e- Mustaffa, Muhammad Shahbaz Aslam, Muhammad Junaid |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |